These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20419513)

  • 1. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
    Beyer C; Distler JH; Distler O
    Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
    Distler JH; Distler O
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v10-1. PubMed ID: 18784126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
    Iwamoto N; Distler JH; Distler O
    Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
    Nishida T; Tsukazaki K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():250-5. PubMed ID: 25831762
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
    Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
    Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
    Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O
    Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
    Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
    Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.
    Akhmetshina A; Dees C; Pileckyte M; Maurer B; Axmann R; Jüngel A; Zwerina J; Gay S; Schett G; Distler O; Distler JH
    FASEB J; 2008 Jul; 22(7):2214-22. PubMed ID: 18326784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Schiffer CA
    N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
    [No Abstract]   [Full Text] [Related]  

  • 11. Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
    Atallah E; Kantarjian H; Cortes J
    Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S105-12. PubMed ID: 17382019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib and the treatment of fibrosis: recent trials and tribulations.
    Gordon J; Spiera R
    Curr Rheumatol Rep; 2011 Feb; 13(1):51-8. PubMed ID: 21086081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
    Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ever-advancing chronic myeloid leukemia treatment.
    Kimura S; Ando T; Kojima K
    Int J Clin Oncol; 2014 Feb; 19(1):3-9. PubMed ID: 24258348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical use of tyrosine kinase inhibitors for treatment of myeloid leukemias].
    Tojo A
    Nihon Rinsho; 2009 Oct; 67(10):1926-31. PubMed ID: 19860192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myeloid leukemia: advances in diagnosis and management.
    Noronha S; Sawyer S
    JAAPA; 2013 Feb; 26(2):26-9. PubMed ID: 23409382
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.